How powerful is CD133 as a cancer stem cell marker in brain tumors?

被引：91

作者：

Cheng, Jin-Xiang ^{[1
]}

Liu, Bo-Lin ^{[1
]}

Zhang, Xiang ^{[1
]}

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, Xijing Inst Clin Neurosci, Dept Neurosurg, Xian 710032, Shaanxi Prov, Peoples R China

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 05期

关键词：

Brain tumor stem cells; Cancer stem cells; CD133; Prognosis; Targeted therapy; HEPATOCELLULAR-CARCINOMA CELLS; ACUTE MYELOID-LEUKEMIA; GLIOMA-CELLS; HEMATOPOIETIC STEM; PROSPECTIVE IDENTIFICATION; PERIVASCULAR NICHE; EPITHELIAL-CELLS; GROWTH-FACTOR; SELF-RENEWAL; EXPRESSION;

D O I：

10.1016/j.ctrv.2009.03.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer stem cells (CSCs) have been identified in a growing number of hematopoietic and solid tissue malignancies and are typically recognized by virtue of the expression of cell surface markers. CD133, a stem cell marker, is now extensively used as a surface marker to identify and isolate brain tumor stem cells (BTSCs) in malignant brain tumors. However, CD133 as the marker to sort BTSCs suffered some controversies. In this review, we reviewed the rise of CD133, analyzed the efficiency of CD133 on identification and isolation of BTSCs, explained some controversial study results and summed up the role of CD 133 and other effective CSCs markers in sorting CSCs in other tumors. We analyzed current limited reports and found that the expression of CD133 was correlated with poor clinical prognosis in brain tumors. Finally, we summarized the mechanisms of chemo- and radio- resistance of CD133+ brain tumor cell, especially emphasized that the aberrant activation of development pathways in BTSCs can be potential targets to BTSCs, and outlined current preclinical studies on killing BTSCs or sensitizing BTSCs to chemo- and radio-therapies. (C) 2009 Elsevier Ltd. All rights reserved.

引用

收藏

页码：403 / 408

页数：6

相关论文

共 90 条

[1] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[2] Targeting cancer stem cells through L1CAM suppresses glioma growth [J].

Bao, Shideng ;

Wu, Qiulian ;

Li, Zhizhong ;

Sathornsumetee, Sith ;

Wang, Hui ;

McLendon, Roger E. ;

Hjehneland, Anita B. ;

Rich, Jeremy N. .

CANCER RESEARCH, 2008, 68 (15) :6043-6048

[3] Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].

Bao, Shideng ;

Wu, Qiulian ;

McLendon, Roger E. ;

Hao, Yueling ;

Shi, Qing ;

Hjelmeland, Anita B. ;

Dewhirst, Mark W. ;

Bigner, Darell D. ;

Rich, Jeremy N. .

NATURE, 2006, 444 (7120) :756-760

[4] Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor [J].

Bao, Shideng ;

Wu, Qiulian ;

Sathornsumetee, Sith ;

Hao, Yueling ;

Li, Zhizhong ;

Hjelmeland, Anita B. ;

Shi, Oing ;

McLendon, Roger E. ;

Bigner, Darell D. ;

Rich, Jeremy N. .

CANCER RESEARCH, 2006, 66 (16) :7843-7848

[5] Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma [J].

Bar, Eli E. ;

Chaudhry, Aneeka ;

Lin, Alex ;

Fan, Xing ;

Schreck, Karisa ;

Matsui, William ;

Piccirillo, Sara ;

Vescovi, Angelo L. ;

DiMeco, Francesco ;

Olivi, Alessandro ;

Eberharta, Charles G. .

STEM CELLS, 2007, 25 (10) :2524-2533

[6] CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors [J].

Beier, Dagmar ;

Wischhusen, Joerg ;

Dietmaier, Wolfgang ;

Hau, Peter ;

Proescholdt, Martin ;

Brawanski, Alexander ;

Bogdahn, Ulrich ;

Beier, Christoph P. .

BRAIN PATHOLOGY, 2008, 18 (03) :370-377

[7] CD133+ and CD133- glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles [J].

Beier, Dagmar ;

Hau, Peter ;

Proescholdt, Martin ;

Lohmeier, Annette ;

Wischhusen, Joerg ;

Oefner, Peter J. ;

Aigner, Ludwig ;

Brawanski, Alexander ;

Bogdahn, Ulrich ;

Beier, Christoph P. .

CANCER RESEARCH, 2007, 67 (09) :4010-4015

[8] Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice [J].

Bhatia, M ;

Wang, JCY ;

Kapp, U ;

Bonnet, D ;

Dick, JE .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (10) :5320-5325

[9] The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells [J].

Bidlingmaier, Scott ;

Zhu, Xiaodong ;

Liu, Bin .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2008, 86 (09) :1025-1032

[10] Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo [J].

Blair, A ;

Hogge, DE ;

Ailles, LE ;

Lansdorp, PM ;

Sutherland, HJ .

BLOOD, 1997, 89 (09) :3104-3112

← 1 2 3 4 5 6 7 8 9 →